Ascendis Pharma

#1789

Rank

$10.44B

Marketcap

Denmark

Country

Leadership team

Mr. Jan Moller Mikkelsen (Pres, CEO, Member of Exec. Board & Exec. Director)

Mr. Michael Wolff Jensen L.L.M. (Sr. VP, Chief Legal Officer & Member of the Exec. Board)

Dr. Birgitte Volck M.D., Ph.D. (Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs)

Products/ Services

Biotechnology, Clinical Trials, Health Care

Number of Employees

500 - 1000

Headquarters

Palo Alto, California, United States

Established

2006

Company Registration

SEC CIK number: 0001612042

Revenue

20M - 100M

Traded as

ASND

Social Media

URL

https://ascendispharma.com

Overview

Location

Recognition and Award

References

Summary

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

History

Ascendis Pharma was founded in 2005 in Copenhagen, Denmark with the mission of revolutionizing treatments for rare and complex diseases. The company built a robust platform with state-of-the-art drug development technologies to provide new treatments for diseases with few or no available treatments.

Mission

Ascendis Pharma creates technologies to transform medicine and enable treatments to reach those with rare and complex diseases across the globe.

Vision

Ascendis Pharma will be recognized as the leader in the development of transformative treatments for rare and complex diseases that provide superior therapeutic benefit with improved convenience and compliance.

Key Team

Mr. Scott T. Smith (CFO, Sr. VP & Member of Exec. Board)

Ms. Lotte Sonderbjerg (Chief Admin. Officer, Sr. VP & Member of the Exec. Board)

Mr. Flemming Steen Jensen (Sr. VP of Product Supply & Quality)

Mr. Peter Rasmussen (VP of Fin. & Principal Accounting Officer)

Dr. Kennett Sprogoe (Sr. VP and Head of Innovation & Research)

Mr. Timothy J. Lee (Sr. Director of Investor Relations)

Dr. Jens Sigurd Okkels Ph.D. (Sr. VP of Product Devel.)

Recognition and Awards

In 2019, Ascendis Pharma received Orphan Drug Designation and Priority Review Status from the FDA for TransCon hGH, an investigational once-weekly, long-acting recombinant human growth hormone therapy. In 2020, they were also awarded the prestigious Frost & Sullivan Digital Health Ecosystem Enabler Award.